MBX Biosciences, Inc. (MBX) research
MBX Biosciences, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $58.51
- As of
MBX Biosciences, Inc. (MBX): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-27.
As of . Source: SEC EDGAR filings for MBX. Method and limitations.
Share the MBX intelligence card
See the full MBX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MBX on one page. Preview it with sample data, then open it live with a free account.
Preview the MBX dossierActive signals for MBX
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 60% of MBX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 56% of MBX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +160% to MBX (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 22.2%, EPS $-0.78 vs $-0.6385 estimate
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 57% of MBX (2026Q1)
FREE, NO ACCOUNT
Every signal on MBX, as it fires
You are seeing 5 of 9 signals recorded on MBX since 2026-06-02.
The five above landed across 3 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MBX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 55287L101 · 2026Q2 | $12.5M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 55287L101 · 2026Q2 | $10.1M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 55287L101 · 2026Q2 | $6.3M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MBX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
MBX against its peers
MBX's return on equity of -23.6% ranks in the 73rd percentile of 23 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | MBX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 33.0M | n/a | 15 |
| Operating margin | n/a | -757.9% | n/a | 14 |
| Net margin | n/a | -694.7% | n/a | 14 |
| Return on equity | -23.6% | -37.9% | 73 | 23 |
Peers (23): PGEN, ATAI, QURE, NAMS, ZLAB, CLDX, DYN, BEAM, IRON, IMNM, NRIX, SLS, RCUS, VERA, VRDN, DNLI, ELVN, GRTX, ADMA, MLYS, PHVS, ARQT, ACAD. Left out: ZLDPF (no annual filing), ADRX (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (MBX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more MBX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MBXand get the insider, 13F, options, and confluence read in one view.